BackgroundLimited studies exist on the outcome of thrombolytic therapy of acute ischemic stroke patients outside of clinical trials.AimTo assess the possible risk factors associated with in-hospital death and symptomatic intracerebral hemorrhage among patients who received intravenous tissue plasminogen activator.MethodsA total of 7193 patients with a clinical diagnosis of acute ischemic stroke and a documented National Institutes of Health Stroke Scale score were treated with intravenous tissue plasminogen activator within 4\uc2\ub75 hours of time last known to be well. Generalized estimating equations modeling was used to assess the associations of in-hospital death and symptomatic intracerebral hemorrhage with clinical characteristics.Re...
Background: Symptomatic Intracerebral hemorrhage (sICH) is a serious complication of recombinant tis...
AbstractThirteen (1.8%) of 708 patients with acute myocardial infarction treated with recombinant ti...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
INTRODUCTION: Acute ischemic stroke is an emergency which can be treated by intravenous thrombolytic...
University of Minnesota M.S. thesis. August 2011. Major: Health services research, policy, and admin...
Stroke is a major health problem worldwide and nationally: the second leading cause of death and dem...
BACKGROUND: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarct...
OBJECTIVE: Scarce data are available on the occurrence of symptomatic intracranial hemorrhage relate...
BACKGROUND AND PURPOSE: Data on long-term outcome after intravenous tissue-type plasminogen activato...
Although treatment with intravenous tissue plasminogen activator (t-PA) improves clinical outcomes i...
Background: Thrombolysis is the standard of treatment for acute ischemic stroke, with a time window ...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic...
<p><b>Background and Purpose:</b> A number of factors have been associated with po...
Background: Symptomatic Intracerebral hemorrhage (sICH) is a serious complication of recombinant tis...
AbstractThirteen (1.8%) of 708 patients with acute myocardial infarction treated with recombinant ti...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
BACKGROUND AND PURPOSE: The prospective trials evaluating the safety and efficacy of intravenous tis...
INTRODUCTION: Acute ischemic stroke is an emergency which can be treated by intravenous thrombolytic...
University of Minnesota M.S. thesis. August 2011. Major: Health services research, policy, and admin...
Stroke is a major health problem worldwide and nationally: the second leading cause of death and dem...
BACKGROUND: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarct...
OBJECTIVE: Scarce data are available on the occurrence of symptomatic intracranial hemorrhage relate...
BACKGROUND AND PURPOSE: Data on long-term outcome after intravenous tissue-type plasminogen activato...
Although treatment with intravenous tissue plasminogen activator (t-PA) improves clinical outcomes i...
Background: Thrombolysis is the standard of treatment for acute ischemic stroke, with a time window ...
BACKGROUND: Although recombinant tissue plasminogen activator (tPA) improves outcomes from ischemic...
<p><b>Background and Purpose:</b> A number of factors have been associated with po...
Background: Symptomatic Intracerebral hemorrhage (sICH) is a serious complication of recombinant tis...
AbstractThirteen (1.8%) of 708 patients with acute myocardial infarction treated with recombinant ti...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...